The Global 3D Printed Drugs Market is set to grow at a CAGR of 6.2% by 2030 and is driven by increasing R&D investments by the market players; says Absolute Markets Insights
3D printing is gaining popularity in the healthcare market and these drugs have largely benefited patients facing issues in swallowing pills. These 3D printed drugs are manufactured by solidifying layers of materials to form a defined 3D structure. The adaptability of 3D printing may also be applied for the unique and precise dosing of medicines, thus, presenting more efficient drug administration. 3D printing is an efficient approach that is expected to enhance the application of various controlled drug release mechanisms, in coming future.
“Presently, the 3D printed drugs market is quite niche with very few number of active companies. However, more number of market players are expected to commercialize their offerings in the next ten years as they are heavily investing into R&D”.
Purchase the complete report titled “The Global 3D Printed Drugs Market” at (https://www.absolutemarketsinsights.com/reports/3D-Printed-Drugs-Market-2018-2026-143)
Presently, 3D printed technology has a very limited adoption. Countries like the U.S. are amongst early adopters with commercialization of products like Spritam by Aprecia Pharmaceuticals. Big pharmaceutical companies including GlaxoSmithKline are investing into the 3D printing drug technology and are expected to enter into this market in near future.
The 3D Printed Drugs report has incorporated both quantitative and qualitative aspects of the industry within each of the regions and countries that are involved in the study. Additionally, the report has been crafted by considering the available opportunities in micro markets for stakeholders to capitalize along with the comprehensive analysis of competitive landscape and product offerings of key players. The geographical analysis done emphasizes on each of the major countries across North America, Asia Pacific, Europe, Middle East and Africa and Latin America.
The competitive landscape demonstrates that presently, there are very few players active in this market. Companies are investing in R&D to innovate and come up with such products in coming future. Some of the players active in the market are GlaxoSmithKline Plc., 3D Printer Drug Machine, Aprecia Pharmaceuticals, Hewlett Packard Caribe, BV, LLC, and FabRx Ltd. amongst others.
Aprecia Pharmaceuticals, a U.S. headquartered company has manufactured a FDA approved drug called Spritam, which disintegrates in the mouth when taken with water. It essentially binds the layers of powdered medicine by a respective layer of liquid that effectively treats onset epilepsy.
3D Printed Drugs Market - by Drug
- Spritam
- Others
3D Printed Drugs Market – by Region
- North America
- U.S.
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- GCC Countries
- Southern Africa
- Rest of Middle East and Africa
- Latin America
- Brazil
- Rest of Latin America